NasdaqGS:PEPGBiotechs
A Look At PepGen (PEPG) Valuation After FREEDOM2 Phase 2 Topline Update
PepGen special call puts Phase 2 FREEDOM2 topline data in focus
PepGen (PEPG) has scheduled a special call to review topline results from the lowest dose 5 mg/kg multiple ascending dose cohort in its ongoing Phase 2 FREEDOM2 study, highlighting favorable safety, splicing and vHOT findings for investors.
See our latest analysis for PepGen.
The recent call around encouraging Phase 2 FREEDOM2 data comes after a sharp reset in sentiment, with a 64.62% 7 day and 73.05% 30 day share price...